What You Should Know:
– Evident, a leader in clinical microscopy and superior optics, today announced a definitive agreement to acquire Pramana, Inc., a manufacturer of digital pathology solutions. Financial details of the acquisition were not disclosed.
– The strategic acquisition brings together Pramana’s cutting-edge autonomous whole slide imaging technologies with Evident’s longstanding expertise to revolutionize the market for digital pathology solutions and usher in what both companies are calling “digital pathology 2.0”.
Expanding Digital Pathology Capabilities
Pramana, founded in 2021 by nference, a leader in Multimodal and Agentic AI innovation, specializes in developing fully autonomous image scanning systems for pathology settings in hospitals, research facilities, and educational institutions. Pramana’s scanners represent a generational advancement, using real-time AI algorithms to optimize efficiency, reduce costs, and enhance safety during the scanning process.
Pramana’s AI-powered imaging solution helps pathologists achieve industry-leading image quality and unprecedented accuracy. Its built-in AI algorithms and automated quality control can eliminate up to 70% of manual workflow steps while capturing previously undetectable tissue features, radically improving clinical diagnostics and research.
With millions of slides being digitized daily by healthcare providers, research labs, molecular science companies, and academic institutions, Pramana’s innovation and capabilities will help Evident keep pace with daily caseloads, automate quality control, seamlessly integrate data and communication systems, and take advantage of the industry’s newest advances in AI-driven imaging and analysis.
“Pramana is dedicated to crafting solutions that empower labs to embrace digital transformation and modernize their workflows. We’ve seen remarkable enthusiasm for our autonomous whole slide imaging systems, and when combined with Evident’s long history of superior optics and proven performance, we see a significant opportunity to accelerate the global adoption of digital pathology and usher in a new era of intelligent imaging systems,” said Murali Aravamudan, Co-founder and CEO of nference and Pramana.
